Panagiotis Antiochos

Dr. Panagiotis Antiochos

orcid

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 October 2024 in Circulation
Verified
Journal Article
Closed access
NMNiccolò Maurizi
Niccolò Maurizi
PAPanagiotis Antiochos
Panagiotis Antiochos
AOAnjali Tiku Owens
Anjali Tiku Owens
NLNeal Lakdawala
Neal Lakdawala
SSSara Saberi
Sara Saberi
Iacopo OlivottoIacopo Olivotto
Iacopo Olivotto
BACKGROUND: Septal reduction therapy (SRT) provides substantial symptomatic improvement in patients with obstructive hypertrophic cardiomyopathy (HCM). However, long-term disease course after SRT and predictors of adverse outcomes have not been systematically examined. METHODS: Data from 13 high clinical volume HCM centers from the international SHARE (Sarcomeric Human Cardiomyopathy Registry) were analyzed. Patients were followed from the time of SRT until last follow-up or occurrence of heart failure (HF) composite outcome (cardiac transplantation, implantation of a left ventricular assist device, left ventricular ejection fraction <35%, development of New York Heart Association class III or IV symptoms), ventricular arrhythmias composite outcome (sudden cardiac death, resuscitated cardiac arrest, or appropriate implantable cardioverter defibrillator therapy), or HCM-related death. Cox proportional hazards models were used to identify predictors of outcome. RESULTS: Of the 10 225 patients in SHARE, 1832 (18%; 968 [53%] male) underwent SRT, including 455 (25%) with alcohol septal ablation and 1377 (75%) with septal myectomy. The periprocedural 30-day mortality rate was 0.4% (8 of 1832) and 1499 of 1565 (92%) had a maximal left ventricular outflow tract gradient <50 mm Hg at 1 year. After 6.8 years (range, 3.4–9.8 years; 12 565 person-years) from SRT, 77 (4%) experienced HCM-related death (0.6% per year), 236 (13%) a composite HF outcome (1.9% per year), and 87 (5%) a composite ventricular arrhythmia outcome (0.7% per year). Among adults, older age at SRT was associated with a higher incidence of HCM death (hazard ratio, 1.22 [95 CI, 1.1–1.3]; P <0.01) and the HF composite (hazard ratio, 1.14 [95 CI, 1.1–1.2] per 5-year increase; P <0.01) in a multivariable model. Female patients also had a higher risk of the HF composite after SRT (hazard ratio, 1.4 [95 CI, 1.1–1.8]; P <0.01). De novo atrial fibrillation occurred after SRT in 387 patients (21%). Among pediatric patients followed for a median of 13 years after SRT, 26 of 343 (16%) developed the HF composite outcome, despite 96% being free of recurrent left ventricular outflow tract obstruction. CONCLUSIONS: Successful short- and long-term relief of outflow tract obstruction was observed in experienced multidisciplinary HCM centers. A subset of patients progressed to develop HF, but event-free survival at 10 years was 83% and ventricular arrhythmias were rare. Older age, female sex, and SRT during childhood were associated with a greater risk of developing HF.

1 January 2016 in Thrombosis and Haemostasis
Verified
Journal Article
Closed access
PDF file
Pedro Marques-VidalPedro Marques-Vidal
Pedro Marques-Vidal
JVJulien Virzi
Julien Virzi
SPSabrina Pagano
Sabrina Pagano
NSNathalie Satta
Nathalie Satta
FBFrançois Bastardot
François Bastardot
NVNicolas Vuilleumier
Nicolas Vuilleumier
Summary: We aimed to determine the association between autoantibodies against apolipoprotein A-1 (anti-apoA-1 IgG) and prevalent cardiovascular (CV) disease (CVD) as well as markers of CV risk in the general population. Cross-sectional data were obtained from 6649 subjects (age 52.6 ± 10.7 years, 47.4 % male) of the population-based CoLaus study. CVD was defined as myocardial infarction, angina pectoris, percutaneous revascularisation or bypass grafting for ischaemic heart disease stroke or transient ischaemic attack, and was assessed according to standardised medical records. Anti-apoA-1 IgG and biological markers were measured by ELISA and conventional automated techniques, respectively. Prevalence of high anti-apoA-1 IgG levels in the general population was 19.9 %. Presence of anti-apoA-1 IgG was significantly associated with CVD [odds ratio 1.34, 95 % confidence interval (1.05–1.70), p=0.018], independently of established CV risk factors (CVRFs) including age, sex, hypertension, smoking, diabetes, low and high-density lipoprotein cholesterol levels. The n=455 (6.8 %) study participants with a history of CVD (secondary prevention subgroup) presented higher median anti-ApoA-1 IgG values compared with subjects without CVD (p=0.029). Among patients in the secondary prevention subgroup, those with positive anti-apoA-1 IgG levels had lower HDL (p=0.002) and magnesium (p=0.001) levels, but increased uric acid and high-sensitivity C-reactive protein levels (p=0.022, and p<0.001, respectively) compared to patients with negative anti-apoA-1 IgG levels. In conclusion, anti-apoA-1 IgG levels are independently associated with CVD in the general population and also related to CV biomarkers in secondary prevention. These findings indicate that anti-apoA-1 IgG may represent a novel CVRF and need further study in prospective cohorts.

18 April 2017 in Frontiers in Immunology
Verified
Journal Article
Open access
PAPanagiotis Antiochos
Panagiotis Antiochos
Pedro Marques-VidalPedro Marques-Vidal
Pedro Marques-Vidal
JVJulien Virzi
Julien Virzi
SPSabrina Pagano
Sabrina Pagano
NSNathalie Satta
Nathalie Satta
NVNicolas Vuilleumier
Nicolas Vuilleumier
Background: Autoantibodies against apolipoprotein A-1 (anti-apoA-1 IgG) have emerged as an independent biomarker for cardiovascular disease and mortality. However, their association with all-cause mortality in the community as well as their possible genetic determinants have not been studied. Objective: To determine whether anti-apoA-1 IgG: a) predict all-cause mortality in the general population, and b) are associated with single–nucleotide polymorphisms (SNPs) in a genome-wide association study (GWAS). Methods: Clinical, biological and genetic data from the population-based, prospective CoLaus study, including 5220 participants (mean age 52.6 years, 47.3% men) followed over a median duration of 5.6 years. The primary study outcome was all-cause mortality. Results: After multivariate adjustment, anti-apoA-1 IgG positivity independently predicted all-cause mortality: hazard ratio (HR)=1.54, 95% Confidence Interval (95%CI): (1.11-2.13), P=0.01. A dose-effect relationship was also observed, each standard deviation of logarithmically transformed anti-apoA-1 IgG being associated with a 15% increase in mortality risk: HR=1.15, 95%CI: (1.02-1.28), P=0.028. The GWAS yielded 9 SNPs belonging to the Fc receptor like-3 (FCRL3) gene that were significantly associated with anti-apoA-1 IgG levels, with the lead SNP (rs6427397, P=1.54×10-9) explaining 0.67% of anti-apoA-1 IgG level variation. Conclusion: Anti-apoA-1 IgG levels a) independently predict all-cause mortality in the general population and b) are linked to FCRL3, a susceptibility gene for numerous autoimmune diseases. Our findings indicate that preclinical autoimmunity to anti-apoA-1 IgG may represent a novel mortality risk factor.

1 December 2017 in Arteriosclerosis, Thrombosis, and Vascular Biology
Verified
Journal Article
Closed access
PAPanagiotis Antiochos
Panagiotis Antiochos
Pedro Marques-VidalPedro Marques-Vidal
Pedro Marques-Vidal
JVJulien Virzi
Julien Virzi
SPSabrina Pagano
Sabrina Pagano
NSNathalie Satta
Nathalie Satta
NVNicolas Vuilleumier
Nicolas Vuilleumier
Objective—: We aimed to determine whether autoantibodies against apoA-1 (apolipoprotein A-1; anti-apoA-1 IgG) predict incident coronary artery disease (CAD), defined as adjudicated incident myocardial infarction, angina, percutaneous coronary revascularization, or bypass grafting, in the general population. We further investigated whether this association is modulated by a functional CD14 receptor single nucleotide polymorphism. Approach and Results—: In a prospectively studied, population-based cohort of 5220 subjects (mean age 52.6±10.7 years, 47.4% males), followed over a median period of 5.6 years, subjects positive versus negative for anti-apoA-1 IgG presented a total CAD rate of 3.9% versus 2.8% ( P =0.077) and a nonfatal CAD rate of 3.6% versus 2.3% ( P =0.018), respectively. After multivariate adjustment for established cardiovascular risk factors, the hazard ratios of anti-apoA-1 IgG for total and nonfatal CAD were: hazard ratio=1.36 (95% confidence interval, 0.94–1.97; P =0.105) and hazard ratio=1.53 (95% confidence interval, 1.03–2.26; P =0.034), respectively. In subjects with available genetic data for the C260T rs2569190 single nucleotide polymorphism in the CD14 receptor gene (n=4247), we observed a significant interaction between anti-apoA-1 IgG and rs2569190 allele status with regards to CAD risk, with anti-apoA-1 IgG conferring the highest risk for total and nonfatal CAD in non-TT carriers, whereas being associated with the lowest risk for total and nonfatal CAD in TT homozygotes ( P for interaction =0.011 and P for interaction =0.033, respectively). Conclusions—: Anti-apoA-1 IgG are independent predictors of nonfatal incident CAD in the general population. The strength of this association is dependent on a functional polymorphism of the CD14 receptor gene, a finding suggesting a gene–autoantibody interaction for the development of CAD.

1 October 2019 in The American Journal of Cardiology
Verified
Journal Article
Closed access
GTGeorgios Tzimas
Georgios Tzimas
PAPanagiotis Antiochos
Panagiotis Antiochos
PMPierre Monney
Pierre Monney
EEEric Eeckhout
Eric Eeckhout
DMDavid Meier
David Meier
JSJürg Schläpfer
Jürg Schläpfer